Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes

Journal of Neuropathology and Experimental Neurology

Volumn 60, Issue 12, 2001, Pages 1170-1180

  Wolter, Marietta ^a   Reifenberger, Julia ^a   Blaschke, Britta ^a   Ichimura, Koichi ^b   Schmidt, Esther E ^b   Collins, V Peter ^b   Reifenberger, Guido ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

DNA methylation; Homozygous deletion; Mutation; Oligodendroglioma; Tumor suppressor genes

Indexed keywords

CYCLIN DEPENDENT KINASE 2; PROTEIN P16;

ADOLESCENT; ADULT; AGED; ALLELE; ANAPLASTIC CARCINOMA; ARTICLE; ASTROCYTOMA; CANCER GENETICS; CHILD; CHROMOSOME 9P; CLINICAL ARTICLE; CORRELATION FUNCTION; DNA METHYLATION; FEMALE; GENE DELETION; GENE EXPRESSION; GENE LOSS; GENE MUTATION; HUMAN; MALE; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0035205570     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/60.12.1170     Document Type: Article

References (45)

1. Oligodendroglial tumours and mixed gliomas
2. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p
3. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors
4. Shared allelic losses on chromosomes lp and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma
5. Molecular genetic aspects of oligodendrogliomas including comparative genomic hybridization
6. Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas
7. Molecular genetic evidence for subtypes of oligoastrocytomas
8. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype
9. Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers
10. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene at 1p32 in oligodendroglial tumors
11. INK4c gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas
12. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
13. Alterations of chromosome arms lp and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas
14. INK4a/CDKN2A tumor suppressor and its relatives
15. The Ink4 family of cell cycle inhibitors in cancer
16. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas
17. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities
18. The ARF/p53 pathway
19. INK4c) in atypical and anaplastic meningiomas
20. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression
21. Mutation of the Von Hippel-Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system
22. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
23. Molecular and cytogenetic analysis of chromosome 9 deletions in 75 gliomas
24. INK4a genes in oligodendrogliomas
25. o growth arrest
26. Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors
27. Alterations in DNA methylation: A fundamental aspect of neoplasia
28. DNA methylation: Past, present and future directions
29. Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B (MTS2/p15) in primary astrocytic tumours
30. Silencing of p16/ CDKN2 expression in human gliomas by methylation and chromatin condensation
31. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis
32. Promoter hypermethylation of the RB1 gene in glioblastomas
33. The role of DNA hypermethylation in human neoplasia
34. CpG island methylator phenotypes in aging and cancer
35. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia
36. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia
37. 6-methylguanine-DNA methyltransferase activity in adult gliomas: Relation to patient and tumor characteristics
38. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
39. p53 mutations in nonastrocytic human brain tumors
40. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 and MDM2 amplification
41. p53 gene mutation and INK4aARF deletion appear to be two mutually exclusive events in human glioblastoma
42. p14ARF deletion and methylation in genetic pathways to glioblastomas
43. ARF) and is amplified in a subset of human breast cancers
44. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus
45. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis